{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:20:52Z","timestamp":1760188852714},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,11]],"date-time":"2006-07-11T00:00:00Z","timestamp":1152576000000},"content-version":"vor","delay-in-days":5123,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[1992,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of plasma\u2010derived coagulation factor concentrates has been marked by the transmission of viral agents. Infusions of factor IX complex concentrates have been additionally complicated by inappropriate thrombosis. Use of these concentrates in the neonate, in those with liver disease, and in surgical patients results in increased risk for this complication. Twenty patients have been infused with a purified coagulation factor IX concentrate for fall\u2010off and recovery studies. A two\u2010compartment model indicated an initial phase half\u2010life of 4.06 \u00b1 2.86 hr and a \u03b2 phase half\u2010life of 20.0 \u00b1 3.8 hr following the administration of AlphaNine\u00ae, Coagulation Factor IX (Human). In vivo recovery was 62.7% \u00b1 13.8%, with an average factor IX coagulant level of 73% \u00b1 16% at 15 min after the infusion of a mean dose of 45 U\/kg. Thirteen previously transfused patients with hemophilia B underwent major orthopedic or general or dental surgery using this purified factor IX. Operative outcomes were excellent in all patients. No excessive bleeding was noted. There was no laboratory or clinical evidence for a disseminated intravascular coagulopathy. The excellent surgical outcomes observed in this multitransfused group with biochemical evidence for active liver disease demonstrates the utility and safety of a purified coagulation factor IX concentrate. \u00a9 1992 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.2830400310","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T13:02:05Z","timestamp":1172062925000},"page":"210-215","source":"Crossref","is-referenced-by-count":24,"title":["Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate"],"prefix":"10.1002","volume":"40","author":[{"given":"Jonathan C.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol K.","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip M.","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward D.","family":"Gomperts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig M.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve W.","family":"Herring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia L.","family":"Novak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,11]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198910263211701"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood.V70.1.276.276","article-title":"Immunologic alternations, HIV seropositivity and seroconversion rates in patients with hemophilia B","volume":"70","author":"Brettler DB","year":"1987","journal-title":"Blood"},{"key":"e_1_2_1_4_2","first-page":"640","article-title":"Clinical use of factor IX concentrates: Report on Thromboembolic complications","volume":"33","author":"Kasper CK","year":"1975","journal-title":"Thromb Diathes Haemorrh"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-81-6-766"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1647857"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-84-6-683"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.1981.03310390055022","article-title":"Myocardial infarction after factor IX therapy","volume":"245","author":"Fuerth JH","year":"1981","journal-title":"J Am Med Assoc"},{"key":"e_1_2_1_9_2","first-page":"645","article-title":"Summary report and recommendations of the task force members and consultants","volume":"33","author":"Menache D","year":"1975","journal-title":"Thromb Diathes Haemorrh"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1001\/jama.1969.03160100038010","article-title":"Prothrombin concentrates in treatment of Christmas disease and allied disorders","volume":"208","author":"Breen FA","year":"1969","journal-title":"J Am Med Assoc"},{"key":"e_1_2_1_11_2","first-page":"159","article-title":"Prothrombin complex concentrates: Potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo","volume":"49","author":"White GC","year":"1977","journal-title":"Blood"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V54.5.1028.1028"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood.V59.2.401.401","article-title":"The coagulant\u2010active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits","volume":"59","author":"Giles AR","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood.V72.4.1269.1269","article-title":"Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals","volume":"72","author":"Smith KJ","year":"1988","journal-title":"Blood"},{"key":"e_1_2_1_15_2","first-page":"665","article-title":"Laboratory identification of intravascular coagulation","volume":"77","author":"Niewiarowski S","year":"1971","journal-title":"J Lab Clin Med"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1182\/blood.V58.3.625.625","article-title":"Labeled factor IX kinetics in patients' with hemophilia B","volume":"58","author":"Smith KJ","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197705000-00003"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.12.2540.2540"},{"issue":"2","key":"e_1_2_1_19_2","first-page":"30","article-title":"Clinical experience of a new monoclonal antibody purified factor IX: Half\u2010life, recovery, and safety in patients with hemophilia B","volume":"27","author":"Kim HC","year":"1990","journal-title":"Semin Hematol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V64.6.1220.1220"},{"key":"e_1_2_1_21_2","unstructured":"MorfiniM LeeM MessoriA and the Factor VIII\/Factor IX Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis: The design and analysis of half\u2010life and recovery studies for factor VIII and factor IX. Thromb Haemostas (in press)."},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30590296380.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1989.tb00832.x"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.2830400310","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.2830400310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T20:50:12Z","timestamp":1698094212000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.2830400310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,7]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1992,7]]}},"alternative-id":["10.1002\/ajh.2830400310"],"URL":"https:\/\/doi.org\/10.1002\/ajh.2830400310","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,7]]}}}